Neuland Laboratories Ltd. · NSE:NEULANDLAB
Neuland Laboratories — Q4 FY2025 Earnings Presentation
37 slides from Neuland Laboratories's earnings presentation, 2025
Slide 1: Neuland Laboratories Limited Investor Presentation Q4FY25 & FY25
Neuland Laboratories Limited Investor Presentation Q4FY25 & FY25
Slide 2: Safe Harbour
SAFE HARBOUR Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "
Slide 3: Table of Content
Table of Content Q3FY25 Highlights Company Overview Business Strategy Our Businesses Shareholder Information Q3FY25 Company Business Our Shareholder Annexure Annexure Highlights Overview Strategy Businesses Information 3
Slide 4: Q4FY25 & FY25 Highlights
Q4FY25 & FY25 Highlights 4
Slide 5: Management Commentary
Management Commentary SUCHETH DAVULURI “We saw marginal decrease in topline in FY25 as compared to FY24. which is further reflected in terms of the decline in operating margins. Nevertheless, these results are in line with our initial outlook at the start of the year regarding our expectations for F
Slide 6: FY25 Business and Financial Highlights
Business and Financial Highlights FY25 Business and Financial Highlights CMS CMS revenues driven by commercial molecules. Increasing interest from Biotech's leading to increase in early-stage projects GDS Specialty business driven by Paliperidone and Dorzolamide In Prime segment Mirtazapine, Levetir
Slide 7: Q4FY25 Financial Highlights
Q4FY25 Financial Highlights Total Income EBITDA PAT* EPS 25.2% (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 22.1% 28.7% 28.9% 98.3 17.3% 22.5% 76.6 20.8% 17.3% 10.2% 101.4 444.4 8.3% 401.9 390.4 128.6 79.0 335.8 315.2 112.2 67.6 52.7 90.3 65.7 58.2 32.0 27.7 24.9 21.6 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q4FY24 Q
Slide 8: FY25 Financial Highlights
FY25 Financial Highlights Total Income EBITDA PAT* EPS (Rs. Cr) (Rs. Cr) (Rs. Cr) (Rs.) 30.2% 19.1% 17.3% 22.9% 233.5 1571.1 474.5 1497.3 299.6 259.4 342.8 202.2 FY24 FY25 FY24 FY25 FY24 FY25 FY24 FY25 Financial Highlights • Total Income for FY25 at Rs. 1,497.3 crore (-4.7% YoY) • EBITDA for FY25 at
Slide 9: Key Balance Sheet Metrics
Key Balance Sheet Metrics Current Ratio(x) ROCE (%) Fixed Asset Turnover (x) Debt to Equity (x) 32.8% 3.1 2.7 2.4 0.2 2.4 2.3 2.1 21.3% 2.1 17.9% 1.7 1.6 1.5 13.5% 0.1 0.1 0.1 9.7% 0.1 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 Particulars (Rs
Slide 10: Key Operating Metrics Q4FY25
Key Operating Metrics Q4FY25 Segment Revenue Prime Specialty Top 10 & Top 5 Products Top 10 Top 10 & Top 5 Customers Top 10 CMS Others Top 5 Top 5 97% 98% 99% 95% 6% 6% 5% 7% 7% 96% 87% 97% 84% 39% 34% 73% 65% 74% 42% 61% 61% 46% 53% 19% 45% 49% 16% 23% 42% 24% 14% 36% 40% 33% 23% 27% Q4FY24 Q1FY25
Slide 11: Key Operating Metrics FY25
Key Operating Metrics FY25 Segment Revenue Prime Specialty Top 10 & Top 5 Products Top 10 Top 10 & Top 5 Customers Top 10 CMS Others Top 5 Top 5 96% 94% 96% 5% 6% 90% 86% 90% 73% 71% 73% 67% 64% 49% 43% 58% 62% 52% 48% 42% 18% 22% 33% 24% FY24 FY25 Prime Specialty CMS Overall Company Prime Specialty
Slide 12: CMS – Revenue Split & Number of Active Projects
CMS – Revenue Split & Number of Active Projects Rs. Cr No. of active CMS projects YoY Movement Q4 FY25 Pre-Clinical P-1 P-2 P-3 Pre-Reg/Reg Commercial Grand Total 462 API 14 12 13 4 4 9 56 511 Intermediate 7 8 7 4 5 10 41 Grand Total 21 20 20 8 9 19 97 303 126 Q4 FY24 Pre-Clinical P-1 P-2 P-3 Pre-Re
Slide 13: Company Overview
Company Overview 13
Slide 14: Company Overview
Company Overview Manufacturing of generic Generic APIs non-exclusive APIs Established in Business 1984 verticals Contract development and 40 years in API manufacturing CDMO Services manufacturing of NCE API and development Total reactor volume of 11,74,000 Liters Facilities Inspected by Supported 3
Slide 15: Key Facts
Key Facts 40+ 980+ 100+ 82% Years of experience DMFs Filed API across 10 diverse Revenue from exports worldwide therapeutic areas 80+ 72 1174* KL 1794 Countries Served Active US DMFs API Manufacturing Employees Capacity *- U3 additional capacity commercial production yet to start 15
Slide 16: Board Of Directors
Board Of Directors Dr. Davuluri D. Sucheth Rao D. Saharsh Rao Dr. Christopher M. Ms. Pallavi Joshi Rama Mohan Rao Vice Chairman & Vice Chairman & Cimarusti Bhakru Executive Chairman Chief Executive Managing Director Non-executive Independent Officer Director Director Ms. Nirmala Murthy Mr. Homi Rust
Slide 17: Key Milestones
Key Milestones Our Journey 2018 2019 2020 2021 2023 2024 Acquisition of Increased flow of projects 100 M+ revenue over Unit – III Crossed INR 10 bn US FDA audit advanced from CMS Japan. 75 live CMS projects Commercialization revenue. of Unit-I intermediates & Active emphasis on supply US FDA audit o
Slide 18: Our Global Presence
Our Global Presence* EUROPE BD office in Lugano, 45% Switzerland Since 2021 APAC NORTH AMERICA BD office in 2% 41% Princeton, New Jersey Since 2004 JAPAN BD office in 1% Tokyo, Japan Since 2007 LATAM INDIA 2% Headquarters in MENA 6% Hyderabad, India 3 Manufacturing Units Manufacturing and Developmen
Slide 19: Manufacturing Facilities Overview
Manufacturing Facilities Overview UNIT - I UNIT - II UNIT - III Bonthapally, Hyderabad 258 kL Pashamylaram, Hyderabad 381 kL Gaddapotharam, Hyderabad 536* kL Year of 1986 1994 2017 Establishment Blocks Block - 1, 2, 3, 4, H, kL & S Block-1, 2, 3, FC, NMSM, Mini plant(A&B) Block - 1, 2, 4, 5, 7 & 8 H
Slide 20: State-of-the-art R&D Centre
State-of-the-art R&D Centre Infrastructure Significant R&D achievements • 15 Development Labs with space • Several NCE APIs added in NDA or for expansion commercial stage drugs • 70 Fume hoods • Support for multiple APIs each year in • Analytical Labs Phase 2 and Phase 3 clinical candidates • Dedica
Slide 21: Regulatory Filings
Regulatory Filings 72 32 10 17 25 DMFs with Filings with Japanese China DMF Filings with USFDA Health Canada DMF filed filed KFDA Korea 28 274 ~499 31 988+ Filings with ROW filings EUDMF filings CEPs received Filings till date TGA including across Germany, for different Turkey, Mexico, France, Polan
Slide 22: Financial Highlights FY2016-2025
Financial Highlights FY2016-2025 Rs. Cr FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 Total Income 511.6 588.9 533.7 670.3 766.6 953.0 953.2 1,200.9 1,571.1 1,497.3 EBITDA 81.5 106.9 54.6 61.4 105.3 162.5 144.3 281.1 474.5 342.8 EBITDA Margin 15.9% 18.1% 10.2% 9.2% 13.7% 17.1
Slide 23: Business Strategy
Business Strategy 23
Slide 24: Neuland Strategy Framework
Neuland Strategy Framework 04 Digitize to enable transparency, compliance, speed of decision making and ease of doing business 01 Invest in new technologies that are valued by our customers and help us differentiate vs. peers 05 Build a world-class talent pipeline and employee value proposition to e
Slide 25: Our Businesses
Our Businesses 25
Slide 26: Generic APIs (GDS)
Generic APIs (GDS) • We are a preferred service provider in the • API manufacturing heritage of over 40 years manufacturing of Active Pharmaceutical Ingredients (APIs) • Flexible 100g to hundreds of tons capacity • Have developed processes for over 100 • Non-competitive advantage (does not APIs with
Slide 27: CDMO Services (CMS)
CDMO Services (CMS) cGMP manufacturing of RSMs/KSMs/Intermediates and APIs for clinical trials and commercial supply Chemistry & manufacturing capabilities Synthetic portion of Carbohydrate Process fermented molecules chemistry optimization IND/NDA filing Deuterated Cyclic and support molecules PEGy
Slide 28: Shareholder Information
Shareholder Information 28
Slide 29: Shareholding Details
Shareholding Details Share Information (as on 31st March 2025) NSE Ticker NEULANDLAB BSE Ticker 524558 Others 34% Market Cap (Rs. Cr) 15,495 Promoters 33% % free-float 67.32% Free-float market cap (Rs. Cr) 10,431 Shares Outstanding 1,28,29,889 3M Average Daily Traded Volume (ADTV) FII DII (Shares)*
Slide 30: Annexure
Annexure 30
Slide 31: Profit & Loss Snapshot (Standalone)
Profit & Loss Snapshot (Standalone) Particulars (Rs Cr) Q4FY25 Q4FY24 YoY (%) Q3FY25 QoQ (%) FY25 FY24 YoY (%) Total Income 335.8 390.4 -14.0% 401.9 -16.4% 1,497.3 1,571.1 -4.7% EBITDA 58.2 112.2 -48.1% 90.3 -35.5% 342.8 474.5 -27.7% EBITDA Margin 17.3% 28.7% -1140 bps 22.5% -520 bps 22.9% 30.2% -73
Slide 32: Revenue & PBT trend
Revenue & PBT trend Rs Cr Revenue 444 415 421 402 395 390 365 336 315 294 259 258 257 270 238 222 203 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 PBT* 130 128 121 110 104 92 84 53 49 39 39 24 28 24 18 13 12 Q4FY21 Q1FY22 Q2FY
Slide 33: Vision and Values
We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration Vision and Values (— Innovation Innovative in everything we do (% Transparency Transparent and open in our communication (a Accountability Accountable for our delivery g Empathy Empathy in
Slide 34: Global peptide API market is poised to reach $94Bn by 2034
Global peptide API market is poised to reach $94Bn by 2034 Global peptide therapeutic /API market in $Bn Key market drivers Peptide therapeutic 38 117 Peptide API market is expected to grow at a market 22.4% CAGR by 2034 due to growing prevalence of chronic disorders such as diabetes and obesity dri
Slide 35: Sustainability Framework
Sustainability Framework Our Key Goals (included in our Executives’ and Focus Our Priorities Our Commitments Goal Area Leaders’ Balanced Scorecard) • Effluent and Waste3’4 • Reduction in direct emissions Direct emissions • FY35: Carbon neutrality: 30%* reduction • Water3’4 • Efforts to water neutral
Slide 36: Glossary
Glossary Term Description Term Description Any substance that is intended for incorporation into a finished drug Drugs (small or large molecule) under development by a Pipeline drugs Active Pharmaceutical product and is intended to furnish pharmacological activity or other manufacturer Ingredient (A
Slide 37: Thank you
Thank you For further information contact IR Desk Neuland Labs Contact: +91 40 6761 1600 Email: mir@Neulandlabs.com Ravi Udeshi / Minakshi Machutre EY IR Contact: +91 22 6192 2000 Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com
Neuland Laboratories — Q4 FY2025 Earnings Presentation on 6ix